Sumida Y, Toyoda H, Yasuda S, Kimoto S, Sakamoto K, Nakade Y
J Atheroscler Thromb. 2024; 31(11):1620-1633.
PMID: 38777770
PMC: 11537790.
DOI: 10.5551/jat.64896.
Chavan S, Rathi P, Mandot A
Clin Exp Hepatol. 2024; 10(1):39-46.
PMID: 38765903
PMC: 11100339.
DOI: 10.5114/ceh.2024.136326.
Keskin M, Avul S, Beyaz A, Koca N
Heliyon. 2024; 10(5):e27291.
PMID: 38486771
PMC: 10937677.
DOI: 10.1016/j.heliyon.2024.e27291.
Vakil Z, Ahire K
Int J Appl Basic Med Res. 2024; 13(4):234-239.
PMID: 38229733
PMC: 10789464.
DOI: 10.4103/ijabmr.ijabmr_138_23.
Aldossari K
Afr Health Sci. 2024; 23(2):509-518.
PMID: 38223606
PMC: 10782311.
DOI: 10.4314/ahs.v23i2.59.
Micropatterned primary hepatocyte co-culture (HEPATOPAC) for fatty liver disease modeling and drug screening.
Cottier K, Bhalerao D, Lewis C, Gaffney J, Heyward S
Sci Rep. 2023; 13(1):15837.
PMID: 37739978
PMC: 10517001.
DOI: 10.1038/s41598-023-42785-9.
Hepatic targeting of the centrally active cannabinoid 1 receptor (CBR) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.
Hirsch S, Hinden L, Naim M, Baraghithy S, Permyakova A, Azar S
J Control Release. 2022; 353:254-269.
PMID: 36442615
PMC: 9900386.
DOI: 10.1016/j.jconrel.2022.11.040.
Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients: A randomized double-blind clinical trial.
Atarodi H, Pazouki A, Gholizadeh B, Karami R, Kabir A, Sadri G
J Res Med Sci. 2022; 27:76.
PMID: 36438071
PMC: 9693701.
DOI: 10.4103/jrms.jrms_683_21.
Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
Assarrar I, Messaoudi N, Elilie Mawa Ongoth F, Abdellaoui W, Malki A, Rouf S
Rev Diabet Stud. 2022; 18(3):140-145.
PMID: 36309775
PMC: 9652707.
DOI: 10.1900/RDS.2022.18.140.
Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years.
Seo I, Lee H, Lee Y
Cardiovasc Diabetol. 2022; 21(1):209.
PMID: 36229839
PMC: 9563513.
DOI: 10.1186/s12933-022-01642-1.
Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.
Shalimar , Elhence A, Bansal B, Gupta H, Anand A, Singh T
J Clin Exp Hepatol. 2022; 12(3):818-829.
PMID: 35677499
PMC: 9168741.
DOI: 10.1016/j.jceh.2021.11.010.
Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.
Moreno-Vedia J, Girona J, Ibarretxe D, Masana L, Rodriguez-Calvo R
Biomedicines. 2022; 10(1).
PMID: 35052876
PMC: 8773613.
DOI: 10.3390/biomedicines10010197.
Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis.
Koulaouzidis G, Charisopoulou D, Kukla M, Marlicz W, Rydzewska G, Koulaouzidis A
Prz Gastroenterol. 2021; 16(3):196-206.
PMID: 34584580
PMC: 8456760.
DOI: 10.5114/pg.2021.109063.
Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
Halfon P, Ansaldi C, Penaranda G, Chiche L, Dukan P, Stavris C
PLoS One. 2021; 16(7):e0254939.
PMID: 34293022
PMC: 8297754.
DOI: 10.1371/journal.pone.0254939.
Association of 45-bp ins/del polymorphism of uncoupling protein 2 (UCP2) and susceptibility to nonalcoholic fatty liver and type 2 diabetes mellitus in North-west of Iran.
Rezapour S, Ahdi Khosroshahi S, Farajnia H, Mohseni F, Khoshbaten M, Farajnia S
BMC Res Notes. 2021; 14(1):169.
PMID: 33957975
PMC: 8101211.
DOI: 10.1186/s13104-021-05586-9.
Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.
Noureddin N, Noureddin M, Singh A, Alkhouri N
Dig Dis Sci. 2021; 67(4):1379-1388.
PMID: 33779880
DOI: 10.1007/s10620-021-06955-x.
Association between nonalcoholic fatty liver disease and inflammatory periodontal disease: A case‑control study.
Duseja A, Chahal G, Jain A, Mehta M, Ranjan A, Grover V
J Indian Soc Periodontol. 2021; 25(1):47-54.
PMID: 33642741
PMC: 7904021.
DOI: 10.4103/jisp.jisp_45_20.
Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease.
Singh A, Garg R, Lan N, Tausif Siddiqui M, Gupta M, Alkhouri N
Indian J Gastroenterol. 2020; 39(6):591-598.
PMID: 33219985
PMC: 9254737.
DOI: 10.1007/s12664-020-01087-y.
Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients.
Dong K, Zhang Y, Huang J, Xia S, Yang Y
Ann Transl Med. 2020; 8(6):308.
PMID: 32355752
PMC: 7186748.
DOI: 10.21037/atm.2020.03.10.
A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities.
Permyakova A, Gammal A, Hinden L, Weitman M, Weinstock M, Tam J
Front Endocrinol (Lausanne). 2020; 11:91.
PMID: 32218769
PMC: 7078689.
DOI: 10.3389/fendo.2020.00091.